Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.35 |
| ▸ | FAP | Q12884 | 3/20 | 0.35 |
| ▸ | PREP | P48147 | 2/20 | 0.35 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.35 |
| ▸ | ARG1 | P05089 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29324711 | 0.85 | CYP2D6 (0.36) | CYP2D6KCNH2HRH3 | |
| SCHEMBL29324707 | 0.84 | CYP2D6 (0.37) | CYP2D6KCNH2HRH3 | |
| SCHEMBL16727344 | 0.80 | CYP2D6 (0.53) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL29324699 | 0.76 | EPHX2 (0.45) | CYP2D6 | |
| SCHEMBL29334537 | 0.75 | DPP4 (0.34) | DPP4CYP2D6KCNH2HRH3 | |
| SCHEMBL29317699 | 0.74 | EPHX2 (0.39) | CYP2D6KCNH2HRH3 | |
| SCHEMBL19981991 | 0.74 | DPP4 (0.43) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL21310237 | 0.74 | DPP4 (0.44) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL19386555 | 0.71 | DPP4 (0.43) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL29321295 | 0.71 | CYP2D6 (0.43) | CYP2D6KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | DPP4 3753/4885DPP7 2363/4885DPP8 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.